- The BTD is based on P-IIa assessing vixarelimab in reducing pruritus in patients with prurigo nodularis
- The study met its 1EPs i.e reduction in WI-NRS from baseline @8wks. in vixarelimab recipients and patients also received PN-IGA score of 0/1 @8wks.
- Kiniksa expects to initiate a P-IIb clinical trial of vixarelimab in prurigo nodularis, evaluating a range of once-monthly dose regimens, by the end of 2021. Vixarelimab is a fully-human mAb that targets oncostatin M receptor beta (OSMRβ)
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Kiniksa